Revenue and Profitability - The company's revenue for Q1 2025 was ¥2,820,969,309.75, a decrease of 3.24% compared to ¥2,915,489,646.11 in the same period last year[4] - Net profit attributable to shareholders increased by 18.50% to ¥184,340,340.89 from ¥155,559,826.48 year-on-year[4] - Basic earnings per share rose by 18.83% to ¥0.0934, compared to ¥0.0786 in the same period last year[4] - Net profit for the current period was CNY 240,798,487.12, an increase of 12.29% compared to CNY 214,428,922.38 in the previous period[14] - Earnings per share (EPS) for the current period was CNY 0.0934, up from CNY 0.0786 in the previous period[14] Cash Flow and Liquidity - The net cash flow from operating activities decreased significantly by 66.06% to ¥37,850,414.72, down from ¥111,518,296.72 in the previous year[4] - Operating cash inflow for the current period was CNY 2,295,889,085.16, an increase of 0.5% from CNY 2,276,286,581.64 in the previous period[16] - Cash inflow from investment activities increased to CNY 4,663,881,764.88, up 22.4% from CNY 3,812,855,758.89 in the previous period[16] - Net cash flow from investment activities improved to CNY 119,334,251.27, compared to a negative CNY 573,043,653.12 in the previous period[16] - Cash inflow from financing activities totaled CNY 2,026,943,005.73, a decrease of 7.6% from CNY 2,194,591,456.31 in the previous period[17] - Net cash flow from financing activities decreased to CNY 219,053,669.61, down 70% from CNY 731,469,429.37 in the previous period[17] - The net increase in cash and cash equivalents was CNY 385,971,915.90, compared to CNY 276,277,439.55 in the previous period[17] - The ending balance of cash and cash equivalents was CNY 3,037,740,916.47, down from CNY 3,104,339,719.27 in the previous period[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥29,838,585,616.20, reflecting a 1.32% increase from ¥29,450,469,334.61 at the end of the previous year[4] - Total current assets increased to CNY 11,760,657,341.32 from CNY 11,276,705,434.24, reflecting a growth of approximately 4.3%[10] - Total liabilities increased to CNY 14,114,956,018.60 from CNY 13,977,060,015.24[12] - Non-current assets totaled CNY 18,077,928,274.88, slightly down from CNY 18,173,763,900.37[12] - The company’s total equity increased to CNY 15,723,629,597.60 from CNY 15,473,409,319.37[12] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 76,797, with no preferred shareholders[8] - The largest shareholder, Tibet Huibang Technology Co., Ltd., holds 18.71% of the shares, totaling 370,449,804 shares[8] Other Income and Expenses - The company reported a significant increase in investment income, which rose by 96.64% to ¥12,700,521.39 from ¥6,458,725.60 year-on-year[6] - Other income increased by 53.42% to ¥19,541,583.62, primarily due to higher government subsidies related to daily operations[6] - The company experienced a 49.77% decrease in contract liabilities, dropping to ¥113,285,447.03 from ¥225,513,904.85 due to reduced advance payments received[6] - The company reported a decrease in research and development expenses to CNY 107,103,304.50 from CNY 94,529,223.40, reflecting a 13.38% increase[13] Financial Reporting - The company did not undergo an audit for the first quarter report[18] - The report was issued by the Board of Directors on April 23, 2025[19]
华邦健康(002004) - 2025 Q1 - 季度财报